ReviewHuman vaccines & immunotherapeutics2014
HIV-1 vaccines: challenges and new perspectives.
Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Immunogenicity of HIV-1Vaccines · 2025Article
- Bioengineered small extracellular vesicles deliver multiple SARS-CoV-2 antigenic fragments and drive a broad immunological response.Journal of extracellular vesicles · 2024Article
- Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Lipophagy confers a key metabolic advantage that ensures protective CD8A T-cell responses against HIV-1.Autophagy · 2021Article
- Broadly neutralizing antibodies and vaccine design against HIV-1 infection.Frontiers of medicine · 2020Review
- Preliminary studies on the use of pertussis toxin for the modulation of intravaginal SIV transmission in rhesus macaques.Journal of medical primatology · 2017Article
- Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.Expert review of vaccines · 2017Review
- Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.Advances in virus research · 2017Review
- Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection.Vaccines · 2016Review
- HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.AIDS research and human retroviruses · 2015Review
- Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward.AIDS patient care and STDs · 2015Review
- Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.Nature communications · 2015Article
- New prospects for a preventive HIV-1 vaccine.Journal of virus eradication · 2015Article
- HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.Vaccine · 2015Review
- An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice.Plant cell reports · 2015Article
- Article
- Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.Human vaccines & immunotherapeutics · 2015Article
- Plant-based vaccines against viruses.Virology journal · 2014Review
- Article
- Which comes first: the antigen or the adjuvant?The Journal of clinical investigation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of a safe and effective preventive HIV-1 vaccine remains a public health priority. Despite scientific difficulties and disappointing results, HIV-1 vaccine clinical development has, for the first time, established proof-of-concept efficacy against HIV-1 acquisition and identified vaccine-associated immune correlates of risk. The correlate of risk analysis showed that IgG antibodies against the gp120 V2 loop correlated with decreased risk of HIV infection, while Env-specific IgA directly correlated with increased risk. The development of vaccine strategies such as improved envelope proteins formulated with potent adjuvants and DNA and vectors expressing mosaics, or conserved sequences, capable of eliciting greater breadth and depth of potentially relevant immune responses including neutralizing and non-neutralizing antibodies, CD4+ and CD8+ cell-mediated immune responses, mucosal immune responses, and immunological memory, is now proceeding quickly. Additional human efficacy trials combined with other prevention modalities along with sustained funding and international collaboration remain key to bring an HIV-1 vaccine to licensure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.